This week in MathOnco 211
Fitness trade-offs, AI, collateral sensitivity, ecological modeling, immunoediting, and more.
“This week in Mathematical Oncology” — May 26, 2022
From the editor:
Today we feature articles on fitness trade-offs, AI, collateral sensitivity, ecological modeling, immunoediting, and more.
"Facts are stupid things, until brought into connection with some general law."
Fundamental immune–oncogenicity trade-offs define driver mutation fitness
David Hoyos, Roberta Zappasodi, Isabell Schulze, Zachary Sethna, …, Taha Merghoub, Arnold J. Levine, Marta Łuksza, Benjamin D. Greenbaum
Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse
Simona Dalin, Beatrice Grauman-Boss, Douglas A. Lauffenburger, Michael T. Hemann
Ecological modelling approaches for predicting emergent properties in microbial communities
Naomi Iris van den Berg, Daniel Machado, Sophia Santos, Isabel Rocha, Jeremy Chacón, William Harcombe, Sara Mitri, Kiran R. Patil
Prospects for the Application of Methods of Evolutionary Biology in Oncology
M. B. Potievskii, P. V. Shegai, A. D. Kaprin
Building digital twins of the human immune system: toward a roadmap
R. Laubenbacher, A. Niarakis, T. Helikar, G. An, B. Shapiro, R. S. Malik-Sheriff, T. J. Sego, A. Knapp, P. Macklin, J. A. Glazier
In Silico Evaluation of Paxlovid’s Pharmacometrics for SARS-CoV-2: A Multiscale Approach
Ferenc A. Bartha, Nóra Juhász, Sadegh Marzban, Renji Han, Gergely Röst
Multi-method global sensitivity analysis of mathematical models
An Dela, Blerta Shtylla, Lisette de Pillis
Cancer Immunoediting in the Era of Immuno-oncology
Matthew M. Gubin, Matthew D. Vesely
Collective directional migration drives the formation of heteroclonal cancer cell clusters
Miriam Palmiero, Laura Di Blasio, Valentina Monica, Barbara Peracino, Luca Primo, Alberto Puliafito
Cancer is complex and dynamic- Ergo, dose optimization calls for mathematical modeling
The Mathematical Oncology Blog
Sandy Anderson, Robert Gillies, Robert Gatenby: “We wish to applaud the sentiments expressed in the recent article in The Cancer Letter titled “Oncologists, advocates, FDA call for an end to MTD and ‘more is better’ era in cancer drug dosing,” but also raise several concerns to be addressed as this initiative moves forward. In particular, we are concerned that proposed methodologies for determining “optimal dosing”—as presented at the April 21 meeting of the FDA Oncologic Drugs Advisory Committee—fail to account for a cancer’s evolving complexity during therapy.”
The newsletter now has a dedicated homepage where we post the cover artwork for each issue. We encourage submissions that coincide with the release of a recent paper from your group.
Caption: “Moving away from MTD dosing requires the treating physician to directly confront the reality of malignant tumors as complex, dynamic, adaptive systems: complex because they consist of multiple cellular and microenvironmental components; dynamic because the components interact with each other through a complex network that changes in space and time; and adaptive because critical elements of the network as well as the network itself can change and adapt to perturbations. Each treatment represents a perturbation of this complex system that elicits equally complex responses—such that optimizing subsequent treatments requires knowledge of the patient, disease, and drug dynamics, as well as the eco-evolutionary responses to the therapy. The image above represents the complexity of tumor growth (adapted from our 2015 Cancer Research paper, “Impact of Metabolic Heterogeneity on Tumor Growth, Invasion, and Treatment Outcomes “). Read more about the implications of cancer’s dynamic complexity on treatment in this recent blog post.”
Postdoctoral position in mathematical oncology (Sandy Anderson, Moffitt)
Current subscriber count: >1.2k